NCT05217069 - FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2019

Primary Completion Date

September 1, 2023

Study Completion Date

October 18, 2023

Conditions

Treatment Related Cancer

Interventions

DRUG

5-FU

400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)

DRUG

Folinic Acid

400mg/m2

DRUG

Irinotecan

180 mg/m2

DRUG

Cetuximab

400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w

DRUG

Avelumab

10mg/kg IV (day 1 q2w)

Trial Locations (1)

Ludwig Maximilians University, Munich